SecBot SecBot

CNTX

Context Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001842952 Biotech & Drug Discovery
$0.2240 −0.02 (−6.67%)
Oct 27 4:00 PM ET · prev $0.2400
Market cap
$21.6M
Nano cap
Median target
🔒 Subscribers only
Next earnings
Nov 11
in 15 days · EPS est. −$0.11
1 year
−81.8%
from $1.23 · Oct 27
30 days
−31.3%
from $0.3260
52-week range
$0.2240–3.36
at the low
Avg volume 20D
966.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 3 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/5 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH Context Therapeutics announced positive interim Phase 1a data for CTIM-76, a CLDN6 x CD3 T cell engager, in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 14 added (0 new), 7 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.096 → −$0.107 over 90 days. 2 up, 3 down in 30 days.

  • TrendDOWNTREND

    35% below its 50-day average. New closing low $0.2240 on Oct 27.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED6,169,250$3.4M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,830,309$1.0M
STATE STREET CORPDOUBLED1,413,428$782.9K
RENAISSANCE TECHNOLOGIES LLCDOUBLED1,041,399$576.8K
JANE STREET GROUP, LLCADD645,209$357.4K
NORTHERN TRUST CORPDOUBLED615,576$341.0K
VANGUARD FIDUCIARY TRUST COADD433,888$240.4K
MARSHALL WACE, LLPNEAR_EXIT384,528$211.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jun 16, 2026Maxim Group
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 24, 2026
Smith Karen L.
Director
AWARD45,000 sh
Jun 24, 2026
Walker Luke Nathaniel
Director
AWARD45,000 sh
Jun 24, 2026
Kantoff Philip W.
Director
AWARD45,000 sh
Jun 24, 2026
Stacey Jennifer Evans
Director
AWARD45,000 sh
Jun 24, 2026
Pasternak Andy
Director
AWARD45,000 sh
Jun 24, 2026
West Linda
Director
AWARD45,000 sh
Feb 19, 2026
Levit Alex C.
Chief Legal Officer, Corp. Sec
AWARD270,000 sh
Feb 19, 2026
Chagin Karen Deborah
Chief Medical Officer
AWARD290,000 sh

Earnings setup

Estimates
Nov 11
reports in 15 days
−$0.11
EPS estimate, this quarter
−12%
estimate change, 90 days
2↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.11-$0.16–-$0.07-11.7%$0.00
Next Q-$0.11-$0.17–-$0.08-7.1%$0.00
Current FY-$0.46-$0.57–-$0.40-17.9%$0.00
Next FY-$0.44-$0.59–-$0.37-1.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Short interest report
Short Interest: CNTX down 32% to 4.7M shares
Settlement 2026-09-30 | Days to cover: 4.03 | ≈5.12% of shares outstanding (est.)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
6,169,250 shares ($3.4M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
1,830,309 shares ($1.0M)
Jun 24, 2026 Insider
Smith Karen L. was granted 45,000 shares
Director
Jun 24, 2026 Insider
Walker Luke Nathaniel was granted 45,000 shares
Director
Jun 24, 2026 Insider
Kantoff Philip W. was granted 45,000 shares
Director
Jun 15, 2026 SEC
Context Therapeutics announced positive interim Phase 1a data for CTIM-76, a CLDN6 x CD3 T cell engager, in heavily…
8-K — Impact 7/10
Jun 15, 2026 Press
Context Therapeutics reported positive interim Phase 1 data for its CLDN6 x CD3 TCE bispecific antibody, CTIM-76…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
CNTX Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Sep 30, 2026
Short interest
Short Interest: CNTX down 32% to 4.7M shares
Settlement 2026-09-30 | Days to cover: 4.03 | ≈5.12% of shares outstanding (est.)
Sep 9, 2026
FDA
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody
Aug 12, 2026
Earnings date
CNTX Q2 2026 Earnings Scheduled — 2026-08-12
Aug 5, 2026
Listing
Listing Status: CNTX — Deficient (was Normal)
Context Therapeutics Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Aug 3, 2026
Earnings date
CNTX Q2 2026 Earnings Scheduled — 2026-08-03

SecBot reports

4 filings · 3 press releases · 2 bullish · 0 bearish · 1 mixed · 1 neutral
All CNTX filing & press-release reports (7)